Market Overview:
The North America generic oncology drug market exhibited strong growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 7% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Generic oncology drug helps in controlling, shrinking and destroying cancer cells that are present in the human body. The drug contains the same active ingredient as of a branded drug for cancer care. A generic oncology drug also accounts for the same quality, performance, intended use, strength, dosage form and route of administration as of branded cancer drug but differs in color or flavor. Other than this, the generic drug yields identical therapeutic effects and efficiently deliver equivalent clinical benefits at lower costs, in comparison with its branded counterpart.
The North America generic oncology drug market is currently being driven by several factors. A rapid increase in the number of smokers, coupled with a rise in sedentary lifestyles, has catalyzed the incidences of cancer cases in the region. On account of this, there has been acceleration in the demand for cost-effective and viable cancer treatments, including generic oncology drugs. Apart from this, rising healthcare investments have resulted in the introduction of several improved and effective generic oncology drugs, thereby positively influencing the market growth in the region. Furthermore, rising technological advancements in the healthcare sector have contributed to early cancer diagnosis, thus propelling the demand for generic oncology drugs at the prevention stage.
IMARC Group’s latest report provides a deep insight into the North America generic oncology drug market covering all its essential aspects. This ranges from macro overview of the market to micro details of the industry performance, recent trends, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc. This report is a must-read for entrepreneurs, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the North America generic oncology drug market in any manner.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the North America generic oncology drug market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on cancer type, drug type and distribution channel.
- Key Regions Analysed
- Analysis for Each Country
- Market by Cancer Type
- Lungs and Bronchus Cancer
- Colon and Rectal Cancer
- Breast Cancer
- Prostate Cancer
- Others
- Market by Drug Type
- Oral Drugs
- Injectables
- Others
- Market by Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Value Chain Analysis
- Key Drivers and Challenges
- Porters Five Forces Analysis
- Competitive Landscape
- Competitive Structure
- Key Player Profiles
Report Coverage:
| Report Features |
Details |
|---|
| Base Year of the Analysis |
2020 |
| Historical Period |
2015-2020 |
| Forecast Period |
2021-2026 |
| Units |
US$ Billion |
| Segment Coverage |
Cancer Type, Drug Type, Distribution Channel, Country |
| Countries Covered |
United States, Canada |
| Customization Scope |
10% Free Customization |
| Report Price and Purchase Option |
Single User License $ 2499
Five User License $ 3499
Corporate License $ 4499 |
| Post-Sale Analyst Support |
10-12 Weeks |
| Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the North America generic oncology drug market performed so far and how will it perform in the coming years?
- What are the key regions in the North America generic oncology drug market?
- What has been the impact of COVID-19 on the North America generic oncology drug market?
- What is the breakup of the North America generic oncology drug market on the basis of cancer type?
- What is the breakup of the North America generic oncology drug market on the basis of drug type?
- What is the breakup of the North America generic oncology drug market on the basis of distribution channel?
- What are the various stages in the value chain of the North America generic oncology drug industry?
- What are the key driving factors and challenges in the North America generic oncology drug industry?
- What is the structure of the North America generic oncology drug industry and who are the key players?
- What is the degree of competition in the North America generic oncology drug industry?
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Generic Oncology Drug Market
5.1 Market Performance
5.2 Market Breakup by Cancer Type
5.3 Market Breakup by Drug Type
5.4 Market Breakup by Distribution Channel
5.5 Market Breakup by Region
5.6 Market Forecast
6 North America Generic Oncology Drug Market
6.1 Market Performance
6.2 Impact of COVID-19
6.3 Market Forecast
7 North America Generic Oncology Drug Market: Breakup by Cancer Type
7.1 Lungs and Bronchus Cancer
7.2 Colon and Rectal Cancer
7.3 Breast Cancer
7.4 Prostate Cancer
7.5 Others
8 North America Generic Oncology Drug Market: Breakup by Drug Type
8.1 Oral Drugs
8.2 Injectables
8.3 Others
9 North America Generic Oncology Drug Market: Breakup by Distribution Channel
9.1 Retail Pharmacies
9.2 Hospital Pharmacies
10 North America Generic Oncology Drug Market: Breakup by Country
10.1 United States
10.1.1 Historical Market Trends
10.1.2 Market Breakup by Cancer Type
10.1.3 Market Breakup by Drug Type
10.1.4 Market Breakup by Distribution Channel
10.1.5 Market Forecast
10.2 Canada
10.2.1 Historical Market Trends
10.2.2 Market Breakup by Cancer Type
10.2.3 Market Breakup by Drug Type
10.2.4 Market Breakup by Distribution Channel
10.2.5 Market Forecast
11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats
12 Value Chain Analysis
13 Porter’s Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Rivalry
13.5 Threat of New Entrants
13.6 Threat of Substitutes
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
List of Figures
Figure 1: Global: Generic Oncology Drug Market: Sales Value (in Billion US$), 2015-2020
Figure 2: Global: Generic Oncology Drug Market: Breakup by Cancer Type (in %), 2020
Figure 3: Global: Generic Oncology Drug Market: Breakup by Drug Type (in %), 2020
Figure 4: Global: Generic Oncology Drug Market: Breakup by Distribution Channel (in %), 2020
Figure 5: Global: Generic Oncology Drug Market: Breakup by Region (in %), 2020
Figure 6: Global: Generic Oncology Drug Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 7: North America: Generic Oncology Drug Market: Sales Value (in Billion US$), 2015-2020
Figure 8: North America: Generic Oncology Drug Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 9: North America: Generic Oncology Drug Market: Breakup by Cancer Type (in %), 2020
Figure 10: North America: Generic Oncology Drug (Lungs and Bronchus Cancer) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 11: North America: Generic Oncology Drug (Lungs and Bronchus Cancer) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 12: North America: Generic Oncology Drug (Colon and Rectal Cancer) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 13: North America: Generic Oncology Drug (Colon and Rectal Cancer) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 14: North America: Generic Oncology Drug (Breast Cancer) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 15: North America: Generic Oncology Drug (Breast Cancer) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 16: North America: Generic Oncology Drug (Prostate Cancer) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 17: North America: Generic Oncology Drug (Prostate Cancer) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 18: North America: Generic Oncology Drug (Other Cancer Types) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 19: North America: Generic Oncology Drug (Other Cancer Types) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 20: North America: Generic Oncology Drug Market: Breakup by Drug Type (in %), 2020
Figure 21: North America: Generic Oncology Drug (Oral Drugs) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 22: North America: Generic Oncology Drug (Oral Drugs) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 23: North America: Generic Oncology Drug (Injectables) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 24: North America: Generic Oncology Drug (Injectables) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 25: North America: Generic Oncology Drug (Other Drug Types) Market: Sales Value (in Billion US$), 2015 & 2020
Figure 26: North America: Generic Oncology Drug (Other Drug Types) Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 27: North America: Generic Oncology Drug Market: Breakup by Distribution Channel (in %), 2020
Figure 28: North America: Generic Oncology Drug Market: Sales Through Retail Pharmacies (in Billion US$), 2015 & 2020
Figure 29: North America: Generic Oncology Drug Market Forecast: Sales Through Retail Pharmacies (in Billion US$), 2021-2026
Figure 30: North America: Generic Oncology Drug Market: Sales Through Hospital Pharmacies (in Billion US$), 2015 & 2020
Figure 31: North America: Generic Oncology Drug Market Forecast: Sales Through Hospital Pharmacies (in Billion US$), 2021-2026
Figure 32: North America: Generic Oncology Drug Market: Breakup by Country (in %), 2020
Figure 33: United States: Generic Oncology Drug Market: Sales Value (in Billion US$), 2015-2020
Figure 34: United States: Generic Oncology Drug Market: Breakup by Cancer Type (in %), 2020
Figure 35: United States: Generic Oncology Drug Market: Breakup by Drug Type (in %), 2020
Figure 36: United States: Generic Oncology Drug Market: Breakup by Distribution Channel (in %), 2020
Figure 37: United States: Generic Oncology Drug Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 38: Canada: Generic Oncology Drug Market: Sales Value (in Billion US$), 2015-2020
Figure 39: Canada: Generic Oncology Drug Market: Breakup by Cancer Type (in %), 2020
Figure 40: Canada: Generic Oncology Drug Market: Breakup by Drug Type (in %), 2020
Figure 41: Canada: Generic Oncology Drug Market: Breakup by Distribution Channel (in %), 2020
Figure 42: Canada: Generic Oncology Drug Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 43: North America: Generic Oncology Drug Industry: SWOT Analysis
Figure 44: North America: Generic Oncology Drug Industry: Value Chain Analysis
Figure 45: North America: Generic Oncology Drug Industry: Porter’s Five Forces Analysis
List of Tables
Table 1: North America: Generic Oncology Drug Market: Key Industry Highlights, 2020 and 2026
Table 2: North America: Generic Oncology Drug Market Forecast: Breakup by Cancer Type (in Billion US$), 2021-2026
Table 3: North America: Generic Oncology Drug Market Forecast: Breakup by Drug Type (in Billion US$), 2021-2026
Table 4: North America: Generic Oncology Drug Market Forecast: Breakup by Distribution Channel (in Billion US$), 2021-2026
Table 5: North America: Generic Oncology Drug Market Forecast: Breakup by Country (in Billion US$), 2021-2026
Table 6: North America: Generic Oncology Drug Market: Competitive Structure
Table 7: North America: Generic Oncology Drug Market: Key Players